Given that, in the present study, biological therapy was a variable of exclusion, further investigations are required to identify whether seropositive patients with RA under anti-TNF-α and anti-IL-6 treatments have fewer EVs and monocytes alterations, possibly related with less systemic inflammation. The gene discussed is TNF; the disease is rheumatoid arthritis.